Posted on 4/17/19
Teva: Here's Why The Future Is Different For This Troubled Pharmaceutical Giant
SummaryTeva has struggled ever since its mistimed an ill-conceived acquisition of Actavis Generics.The generic drug market is finally bottoming out and Teva is poised to benefit . . .
Posted on 3/26/19
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
Summary Proposed deal deeply undervalues Celgene, and BMS admits it. Celgene’s pipeline is about to turn a corner with potentially 5 product launches in the next . . .
Posted on 3/26/19
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
Summary Proposed deal deeply undervalues Celgene, and BMS admits it. Celgene’s pipeline is about to turn a corner with potentially 5 product launches in the next . . .
Posted on 3/26/19
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
SummaryProposed deal deeply undervalues Celgene, and BMS admits it.Celgene’s pipeline is about to turn a corner with potentially 5 product launches in the next 2 years.Bristol-Myers . . .
Posted on 7/10/18
Bank Of America: The Other Parts Matter
In my last article regarding Bank of America (BAC), I explained why its stock can go much higher due to strong growth in its Consumer and . . .
Posted on 2/13/18
Newell Brands: A Safe Bet On Retail
Oh Newell! Newell Brands (NWL) owns some of the most iconic products within our everyday lives. Do you have a Sharpie® or Parker® pen lying around . . .
Charlotte Raleigh
